Sponsor

General Committee of Teaching Hospitals and Institutes, Egypt

Clinical research sponsor

Published trials14
Recruiting shown0
Roles2
SourceClinicalTrials.gov

Clinical trials

14 shown
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
Alterations in Mast Cell and Macrophage Infiltration, as Well as Micro Vessel DensityNCT07448896 · lead sponsor · 2026-04-15
COMPLETED
Obesity on the Efficacy of Bilateral Tibial Nerve StimulationNCT07390682 · lead sponsor · 2026-02-15
COMPLETED
Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve GastrectomyNCT07806448 · lead sponsor · 2025-07-17
COMPLETED
Awake Video Stylet Airway Assessment and Evaluation of Tracheal Intubation With CMAC D-Blade Versus Video Stylet in Bariatric SurgeryNCT06981923 · lead sponsor · 2025-05-10
COMPLETED
Banded Versus Non-Banded Sleeve in Class IV Obese PatientsNCT07100327 · lead sponsor · 2022-06-15
COMPLETED
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.NCT05285397 · lead sponsor · 2022-03-10
UNKNOWN
Evaluation and Re-evaluation of Post-mastectomy Pain Syndrome by Breast Cancer EDGE Task Force OutcomesNCT05458154 · lead sponsor · 2021-03-03
COMPLETED
Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)NCT02138331 · lead sponsor · 2014-04-01
UNKNOWN
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk FactorsNCT07077525 · collaborator · 2023-06-01
COMPLETED

Sponsor roles

lead sponsor13
collaborator1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.